SAFC Pharma selected as Alzheimer's partner

SAFC Pharma has been appointed by BTG to provide chemical development services relating to BGC20-1259, a potential treatment for Alzheimer's disease. BGC20-1259 is currently in Phase I clinical studies, and is a unique, multifunctional compound being developed to target the cognitive impairment and behavioural aspects of Alzheimer's disease, and to provide neuroprotection. The company's chemists will conduct process R&D studies on the synthesis of the drug to determine a suitable process for the production of sufficient quantities for clinical trials. cGMP manufacturing of the compound is anticipated by SAFC following this process development.

"We are delighted that BTG has selected SAFC as its chemical development partner for BGC20-1259," commented Frank Wicks, SAFC president. "Our preclinical chemical support expertise and extensive knowledge in this area has resulted in a positive response from the pharmaceutical industry, demonstrated by our continued growth in the chemistry services and custom manufacturing business."